{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260402989361/en/European-Commission-Approves-KEYTRUDA%C2%AE-pembrolizumab-Plus-Paclitaxel-%C2%B1-Bevacizumab-for-the-Treatment-of-Adults-With-PD-L1-CPS-%E2%89%A51-Platinum-Resistant-Recurrent-Ovarian-Carcinoma-Who-Have-Received-One-or-Two-Prior-Systemic-Treatment-Regimens", "message": "News view counter 641895 successfully enlarged"}